Abstract:Alport syndrome is a hereditary kidney disease characterized by progressive renal failure especially for patients with autosomal recessive and X-linked inheritance.1Kashtan C.E. Alport syndrome: achieving early diagnosis and treatment.Am J Kidney Dis. 2021; 77: 272-279https://doi.org/10.1053/j.ajkd.2020.03.026Abstract Full Text Full Text PDF PubMed Scopus (25) Google Scholar At present, no preventive or curative therapies are available. Current treatment includes the use of renin-angiotensin-aldosterone system inhibitors which slow progression of kidney disease and prolong life expectancy.2Chavez E. Rodriguez J. Drexler Y. Fornoni A. Novel therapies for Alport syndrome.Front Med (Lausanne). 2022; 9848389https://doi.org/10.3389/fmed.2022.848389Crossref PubMed Scopus (2) Google Scholar Though the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial suggests a beneficial effect of SGLT2 inhibitors (SGLT2i) in chronic kidney disease of nonmetabolic origin,3Heerspink H.J.L. Stefánsson B.V. Correa-Rotter R. et al.Dapagliflozin in patients with chronic kidney disease.N Engl J Med. 2020; 383: 1436-1446https://doi.org/10.1056/NEJMoa2024816Crossref PubMed Scopus (1125) Google Scholar whether a conclusion can be extrapolated for the treatment of rapidly progressive genetic kidney disease is unknown.2Chavez E. Rodriguez J. Drexler Y. Fornoni A. Novel therapies for Alport syndrome.Front Med (Lausanne). 2022; 9848389https://doi.org/10.3389/fmed.2022.848389Crossref PubMed Scopus (2) Google Scholar Therefore, we explored the efficacy and safety of SGLT2i in adult autosomal recessive Alport syndrome.This was a real-world study based on our dynamic cohort of Alport syndrome (Supplementary Methods and Supplementary Table S1 Supplementary Table S1). With a follow-up of 4 to 6 months, proteinuria showed a decreasing trend in all the 3 cases of autosomal recessive Alport syndrome, with 24-hour proteinuria decreasing by 0.17 g/24h (8.9%), 0.61 g/24h (39.9%), and 0.69 g/24h (52.3%) respectively (Figure 1). Urinary albumin-creatinine ratio decreased by 374.92 mg/g (26.9%), 561.03 mg/g (44.0%), and 234.33 mg/g (68.7%), respectively. Correspondingly, the serum albumin showed an increment on the whole. Importantly, the serum creatinine and estimated glomerular filtration rate remained stable. No patient discontinued dapagliflozin due to safety concerns and no clinically adverse effect was observed.In this report, the good efficacy of dapagliflozin is reported for the first time in patients with autosomal recessive Alport syndrome who presented with decreased renal function. Proteinuria decreased steadily after administration of dapagliflozin. No patient discontinued SGLT2i therapy due to safety concerns during the follow-up period of 6 months. Limitations should be acknowledged. First, the study included patients with mild or moderate proteinuria, rather than nephrotic proteinuria. Second, this is a pilot study, and more high quality studies with control samples are needed to verify our results.In conclusion, the pilot study showed good efficacy and tolerance of half-dose dapagliflozin in patients with Alport syndrome. Application of SGLT2i as an add-on therapy may be considered. A high quality study with a larger number of patients given full dose dapagliflozin is needed in the future.DisclosureAll the authors declared no conflict of interest. Alport syndrome is a hereditary kidney disease characterized by progressive renal failure especially for patients with autosomal recessive and X-linked inheritance.1Kashtan C.E. Alport syndrome: achieving early diagnosis and treatment.Am J Kidney Dis. 2021; 77: 272-279https://doi.org/10.1053/j.ajkd.2020.03.026Abstract Full Text Full Text PDF PubMed Scopus (25) Google Scholar At present, no preventive or curative therapies are available. Current treatment includes the use of renin-angiotensin-aldosterone system inhibitors which slow progression of kidney disease and prolong life expectancy.2Chavez E. Rodriguez J. Drexler Y. Fornoni A. Novel therapies for Alport syndrome.Front Med (Lausanne). 2022; 9848389https://doi.org/10.3389/fmed.2022.848389Crossref PubMed Scopus (2) Google Scholar Though the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial suggests a beneficial effect of SGLT2 inhibitors (SGLT2i) in chronic kidney disease of nonmetabolic origin,3Heerspink H.J.L. Stefánsson B.V. Correa-Rotter R. et al.Dapagliflozin in patients with chronic kidney disease.N Engl J Med. 2020; 383: 1436-1446https://doi.org/10.1056/NEJMoa2024816Crossref PubMed Scopus (1125) Google Scholar whether a conclusion can be extrapolated for the treatment of rapidly progressive genetic kidney disease is unknown.2Chavez E. Rodriguez J. Drexler Y. Fornoni A. Novel therapies for Alport syndrome.Front Med (Lausanne). 2022; 9848389https://doi.org/10.3389/fmed.2022.848389Crossref PubMed Scopus (2) Google Scholar Therefore, we explored the efficacy and safety of SGLT2i in adult autosomal recessive Alport syndrome. This was a real-world study based on our dynamic cohort of Alport syndrome (Supplementary Methods and Supplementary Table S1 Supplementary Table S1). With a follow-up of 4 to 6 months, proteinuria showed a decreasing trend in all the 3 cases of autosomal recessive Alport syndrome, with 24-hour proteinuria decreasing by 0.17 g/24h (8.9%), 0.61 g/24h (39.9%), and 0.69 g/24h (52.3%) respectively (Figure 1). Urinary albumin-creatinine ratio decreased by 374.92 mg/g (26.9%), 561.03 mg/g (44.0%), and 234.33 mg/g (68.7%), respectively. Correspondingly, the serum albumin showed an increment on the whole. Importantly, the serum creatinine and estimated glomerular filtration rate remained stable. No patient discontinued dapagliflozin due to safety concerns and no clinically adverse effect was observed. In this report, the good efficacy of dapagliflozin is reported for the first time in patients with autosomal recessive Alport syndrome who presented with decreased renal function. Proteinuria decreased steadily after administration of dapagliflozin. No patient discontinued SGLT2i therapy due to safety concerns during the follow-up period of 6 months. Limitations should be acknowledged. First, the study included patients with mild or moderate proteinuria, rather than nephrotic proteinuria. Second, this is a pilot study, and more high quality studies with control samples are needed to verify our results. In conclusion, the pilot study showed good efficacy and tolerance of half-dose dapagliflozin in patients with Alport syndrome. Application of SGLT2i as an add-on therapy may be considered. A high quality study with a larger number of patients given full dose dapagliflozin is needed in the future. DisclosureAll the authors declared no conflict of interest. All the authors declared no conflict of interest. Support was provided by National Science Foundation of China ( 82022010 ); Beijing Natural Science Foundation ( Z190023 ); Chinese Academy of Medical Sciences ( CAMS) Innovation Fund for Medical Sciences ( 2019-I2M-5-046 ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The data will be available on request. The patients have given consent for their clinical information to be published in the journal. Supplementary Material Download .pdf (.11 MB) Help with pdf files Supplementary File (PDF)Supplementary Methods.Table S1. Main effects of SGLT2 inhibitors (dapagliflozin 5 mg) in 3 adults with autosomal recessive Alport syndrome. Download .pdf (.11 MB) Help with pdf files Supplementary File (PDF) Supplementary Methods. Table S1. Main effects of SGLT2 inhibitors (dapagliflozin 5 mg) in 3 adults with autosomal recessive Alport syndrome.

Usefulness of Dapagliflozin for Nephrotic Syndrome Secondary to Diabetic Kidney Disease

Effects of Dapagliflozin in Patients with Membranous Nephropathy

Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes

Impact of Dapagliflozin Adjunctive Therapy on the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 2-5: A systematic review and meta-analysis

Dapagliflozin for rheumatic musculoskeletal disease in patients with chronic kidney disease

The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria

Summary of Research: Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan

Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan

Efficacy and safety of dapagliflozin in children with kidney disease: real-world data

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction

Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence

Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function

Clinical value of adding Dapagliflozin in patients with nephrotic syndrome

Dapagliflozin in Heart Failure and Acute Myocardial Infarction: A Systematic Review of the Association in Diabetic Patients

Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety

Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Efficacy of Dapagliflozin in Adult Autosomal Recessive Alport Syndrome

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease